iRadimed (NASDAQ:IRMD) Releases FY 2025 Earnings Guidance

iRadimed (NASDAQ:IRMD) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 1.840-1.880 for the period, compared to the consensus estimate of 1.750. The company issued revenue guidance of $82.5 million-$83.5 million, compared to the consensus revenue estimate of $81.1 million. iRadimed also updated its Q4 2025 guidance to 0.470-0.510 EPS.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Wall Street Zen downgraded shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Roth Capital set a $90.00 target price on shares of iRadimed in a research note on Friday. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of iRadimed in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company’s stock. According to MarketBeat, iRadimed has a consensus rating of “Buy” and a consensus price target of $81.00.

iRadimed Trading Up 0.5%

Shares of IRMD stock opened at $76.81 on Monday. iRadimed has a 1 year low of $46.86 and a 1 year high of $80.64. The firm’s fifty day moving average price is $73.14 and its two-hundred day moving average price is $63.84. The firm has a market capitalization of $976.64 million, a P/E ratio of 47.41 and a beta of 1.02.

Insiders Place Their Bets

In other iRadimed news, Director Monty K. Allen sold 1,102 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $69.10, for a total value of $76,148.20. Following the completion of the sale, the director owned 19,898 shares in the company, valued at $1,374,951.80. This trade represents a 5.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction on Monday, October 27th. The shares were sold at an average price of $77.69, for a total transaction of $388,450.00. Following the completion of the sale, the chief executive officer owned 2,327,500 shares of the company’s stock, valued at approximately $180,823,475. This represents a 0.21% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 36,102 shares of company stock valued at $2,623,848. Corporate insiders own 36.80% of the company’s stock.

Institutional Trading of iRadimed

A number of hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its position in iRadimed by 1.1% during the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after acquiring an additional 1,821 shares during the period. Qube Research & Technologies Ltd grew its holdings in shares of iRadimed by 2.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 48,537 shares of the medical equipment provider’s stock valued at $2,902,000 after purchasing an additional 964 shares during the last quarter. Raymond James Financial Inc. grew its holdings in shares of iRadimed by 4.7% during the 2nd quarter. Raymond James Financial Inc. now owns 42,952 shares of the medical equipment provider’s stock valued at $2,568,000 after purchasing an additional 1,918 shares during the last quarter. Lazard Asset Management LLC grew its holdings in shares of iRadimed by 5.2% during the 2nd quarter. Lazard Asset Management LLC now owns 41,110 shares of the medical equipment provider’s stock valued at $2,457,000 after purchasing an additional 2,036 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in iRadimed by 14.7% during the 1st quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock worth $1,354,000 after acquiring an additional 3,307 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.